Evidence map›Paper›PMID 40038163›Full record

ArticleEuropean journal of pediatrics2025

Evaluation of the safety of doxapram in premature neonates born before 28 weeks of gestation.

Lauren Saade, Elodie Zana-Taïeb, Pierre-Henri Jarreau, Valérie Biran, Mouna Loukil, Ludovic Tréluyer, Héloïse Torchin

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lauren SaadeDepartment of Neonatal Medicine of Port-Royal, Cochin Hospital, FHU PREMA, AP-HP Centre - Université Paris Cité, 123 Boulevard de Port Royal, 75014, Paris, France. lauren.saade@aphp.fr.
Elodie Zana-TaïebDepartment of Neonatal Medicine of Port-Royal, Cochin Hospital, FHU PREMA, AP-HP Centre - Université Paris Cité, 123 Boulevard de Port Royal, 75014, Paris, France.
Pierre-Henri JarreauDepartment of Neonatal Medicine of Port-Royal, Cochin Hospital, FHU PREMA, AP-HP Centre - Université Paris Cité, 123 Boulevard de Port Royal, 75014, Paris, France.
Valérie BiranNeonatal Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, Robert Debré Children's Hospital, University Paris-Diderot, Sorbone Paris Cité, Inserm U1141, Paris, France.
Mouna LoukilDepartment of Obstetrics and Gynecology of Port-Royal, Cochin Hospital, AP-HP Centre - Université Paris Cité, 75014, Paris, France.
Ludovic TréluyerDepartment of Neonatal Medicine of Port-Royal, Cochin Hospital, FHU PREMA, AP-HP Centre - Université Paris Cité, 123 Boulevard de Port Royal, 75014, Paris, France.
Héloïse TorchinDepartment of Neonatal Medicine of Port-Royal, Cochin Hospital, FHU PREMA, AP-HP Centre - Université Paris Cité, 123 Boulevard de Port Royal, 75014, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To assess the short-term safety of doxapram for treating apnea of prematurity. This is a retrospective and bicenter study. Eligible children were born before 28 weeks of gestation from January 1, 2020 to December 31, 2021. The association between doxapram treatment and gastrointestinal events was assessed with logistic regression models with adjustment for the main confounding factors: center, sex, intra-uterine growth restriction and gestational age. The main outcome measures are gastrointestinal events (necrotizing enterocolitis or feeding intolerance), the adverse effects of doxapram most frequently reported in the literature. The population consisted of 268 children; 113 (42.2%) received doxapram. As compared with children who did not receive doxapram, those who did had lower gestational age at birth (25.4 vs 26.3 weeks), lower birth weight and more evidence of greater clinical respiratory severity. Doxapram treatment was not associated with increased risk of gastrointestinal events (30.1% and 29.7% in the treated and untreated groups; odds ratio 1.3, 95% CI 0.7-2.4, p = 0.43). More children in the treated than untreated group had high blood pressure (25.7% vs 6.5%).

conclusionIn children born before 28 weeks of gestation, doxapram treatment for apnea of prematurity was not associated with the occurrence of gastrointestinal events. WHAT IS KNOWN: • Doxapram is a well-known second-line treatment for apnea of prematurity. It is a central nervous stimulant that can be used in refractory apnea of prematurity despite continuous positive airway pressure and optimal caffeine therapy. However, its use varies among countries and centers, probably because of suspected adverse effects. Studies suggest that this drug may have potential side effects such as digestive events (necrotizing enterocolitis). WHAT IS NEW: • We present reassuring data on the digestive safety of doxapram. Use of this drug was not associated with increased rates of digestive events in preterm infants born before 28 weeks of gestation.

Indexed as

ApneaDoxapramEnterocolitis, NecrotizingInfant, Premature, DiseasesCentral Nervous System StimulantsFemaleGestational AgeHumansInfant, NewbornInfant, PrematureMaleRetrospective StudiesCentral Nervous System StimulantsDoxapramApnea of prematurityNeonatology

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.